Epstein Secrets

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Date: Fri, 24 Jul 2015 20:37:24 +0000 Have

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FDA Approv

From: Sultan Bin Sulayem To: Jeffrey Epstein <[email protected]> Subject: Fwd: FD

worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M., Founder, President, and Chief Executive Officer, Regeneron. "Praluent represents the culmination of more than a decade of tireless work to tra

From: Sultan Bin Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today Importance: — High Have you heard of this co

Sulayern Sent: 7/24/2015 8:37:24 PM To: Jeffrey Epstein [[email protected]] Subject: Fwd: FDA Approve

worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M.D., Ph.D., Founder, President, and Chief Executive Officer, Regeneron. "Praluent represents the culmination of more than a decade of tireless work

From: jeffrey E. [[email protected]] Sent: 7/24/2015 8:47:39 PM To: Sultan Bin Sulayern Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug t

worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M.D., Ph.D., Founder, President, and Chief Executive HOUSE_OVERSIGHT_026364 --- PAGE BREAK --- Officer, Regeneron. "Praluent represents the culmi